All Title Author
Keywords Abstract

The Comparison of the Levels of Leukotriene B4, TGF-β1, Collagen in Keloid Fibroblasts and Normal Skin Fibroblast

DOI: 10.4236/oalib.1102801, PP. 1-7

Subject Areas: Dermatology

Keywords: Collagen, Keloid Fibroblast Leukotriene B4, TGF-β1

Full-Text   Cite this paper   Add to My Lib


Keloid pathogenesis occurs due to the longer duration of inflammation and the increase in the production of several factors such as TGF-β1 that causes the increase of fibroblast proliferation and collagen synthesis. The role of B4 Leukotriene (LTB4) in keloid pathogenesis particularly in the inflammation phase and tissue proliferation has not been clearly elucidated. The present study was to analyze the levels of LTB4, TGF-β1 and collagen in keloid fibroblast and normal skin fibroblast. Fibroblasts were cultured by applying explant method to the keloid and normal skin of the petient with the keloid. The measurement of the levels of LTB4, TGF-β1 and collagen was conducted by using Elisa method and triplicate was conducted subsequently. Statistic testing was performed through unpaired t test. The experiment was carried out in cell culture laboratory of The Faculty of Medicine Padjajaran University Bandung. The levels of LTB4, TGF-β1 are higher in keloid fibroblast, despite the fact that it does not show statistically significant difference. The level of collagen 1 is higher than that of collagen 3 in keloid fibroblast. Leukotriene B4 (LTB4) is one of the derivative of arachidonic acid that plays the role as lipid mediumtor of inflammation and fibroblast chemoattractant. The levels of LTB4, TGF-β1, collagen 1 and collagen 3 increase in keloid fibroblast. Such a result shows the role of LTB4 in the inflammation process that stretches in keloid pathogenesis.

Cite this paper

Kurniawati, Y. , Suwarsa, O. , Agung, A. and Adi, S. (2016). The Comparison of the Levels of Leukotriene B4, TGF-β1, Collagen in Keloid Fibroblasts and Normal Skin Fibroblast. Open Access Library Journal, 3, e2801. doi:


[1]  Dolores, W., Tzankov, A., Pulzi, P. and Hildegunde, P.K. (2009) Hypertrophic Scar and Keloids—A Review of Their Pathophysiology, Risk Factors, and Therapeutic Management. Dermatologic Surgery, 35, 171-181.
[2]  Gauglitz, G.G., Korting, H.C., Pavicic, T., Ruzicka, T. and Marc, G.J. (2011) Hypertrophic Scar and Keloids: Pathomechanisms and Curret and Emerging Treatment Strategies. Molecular Medicine, 17, 113-125.
[3]  Devika, R. And dan Arockiamary, S.N. (2011) Aetiology of Keloids—An Overview. Research in Biotechnology, 2011, 37-43.
[4]  Huang, C.Y. and Ogawa, R. (2013) Roles of Lipid Metabolism in Keloid Development. Lipid in Health and Disease, 2013, 12-60.
[5]  Huang, C.Y. and Ogawa, R. (2012) Fibroproliferative Disorders and Their Mechanobiology. Connective Tissue Re- search, 53, 187-196.
[6]  Bran, G.M., Goessler, U.R., Hormann, K., Riedel, F. and Sadick, H. (2009) Keloids: Current Concepts of Pathogenesis (Review). International Journal of Molecular Medicine, 24, 283-293.
[7]  Bienias, W. and Kaszuba, A. (2012) Keloids: Current Prophylactic and Therapeutic Methods. Postep Derm Alergol, XXIX, 6, 446-450.
[8]  Satori, V.F. (2012) Mechanisms of Wound Repair, Wound Healing and Wound Dressing. In: Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J., Wolff, K., Eds., Fitzpatricks Dermatology in General Medicine, 8th Edition, Mc GrawHill, New York, 2984-2994.
[9]  Profyris, C., Christos, T. and Isabel, D.V. (2012) Cutaneous Scarring: Pathophysiology, Molecular Mechanisms, and Scar Reduction Therapeutics Part I. The Molecular Basis of Scar Formation. Journal of the American Academy of Der- matology, 66, 1-10.
[10]  Scheml, S., Rolf Markus, S., Prantl, L., Landthaler, M. and Babilas, P. (2010) Wound Healing in the 21st Century. Journal of the American Academy of Dermatology, 63, 866-881.
[11]  Sadik, C.D. and Luster, A.D. (2012) Lipid-Cytokine-Chemokine Cascade Orcherstrate Leukocyte Recruitment in Inflammation. Journal of Leukocyte Biology, 91, 207-315.
[12]  Sharma, J.N. and Mohammed, L.A. (2006) The Role of Leukotrienes in the Pathophysiology of Inflammatory Disorders: Is There a Case for Revisiting Leukotriene as Therapeutic Targets? Inflammopharmacology, 14, 10-16.
[13]  Su, W.-H., Ming, H.C., Wen, L.L., Tsung, S.T., Wen, H.C., Chien, S.C. and Peng, H.W. (2010) Non Steroid Anti Inflammatory Drugs for Wounds: Pain Relief or Excessive Scar Formation? Mediumtor of Inflammation, 2010, Article ID: 413238.
[14]  Mathis, S., Venkatakrishna, R.J. and Boddulur, I.H. (2007) Role of Leukotriene B4 Receptors in Rheumatoid Arthritis. Autoimmunity Reviews, 7, 12-17.
[15]  Louw, L. (2000) Keloids in Rural black South Africans. Part 1: General Overview and Essential Fatty Acid Hypotheses for Keloid Formation and Prevention. Prostaglandins, Leukotrienes and Essential Fatty Acids, 63, 237-245.
[16]  Izumo, T., Kondo, M., Arai, N. and Nagai, A. (2010) Role of Leukotriene B4 Reseptor Antagonist in Pulmonal Fibrosis. Annals of Respiratory Medicine, 1-5.
[17]  Sylwia, C., Krzysztof, K., Marek, B. and Otylia, K.B. (2012) The Role of Leukotrienes in the Pathogenesis of Systemic Sclerosis. Folia Histochemica et Cytobiologica, 50, 180-185.
[18]  Biren, N.S., Nitin, P.P. and Priyanka, P. (2008) Role of Leukotriene in Inflammation and Antileukotriene Therapy. Journal of Pharmacy Research, 1, 113-125.
[19]  Akira, T. (1998) Establishment of Fibroblast Cultures. Current Protocols in Cell Biology, 2.1.1-2.1.12.
[20]  Bommie, F.S., Jun, Y.L. and Sung, N.J. (2013) Models of Abnormal Scarring. BioMed Research International, 2013, Article ID: 423147.
[21]  Vanina, M.T.V., Bernardo, H., Jeronimo, P.F. and Lydia, M.F. (2010) Keloid Explant, Culture: A Model for Keloid Fibroblasts Isolation and Cultivation Based on the Biological Differences of Its Specific Regions. International Wound Journal, 7, 339-348.
[22]  Syed, F., Ahmadi, E., Iqbal, S.A., Singh, S., McGrouther, D.A. and Bayat, A. (2011) Fibroblast from the Growing Margin of Keloid Scars Produce Higher Levels of Collagen I and III Compared with Intralesional and Extralesional Sites: Clinical Implications for Lesional Site-Directed Therapy. British Journal of Dermatology, 164, 83-96.
[23]  Jie, L., Zuleika, L.B.M. and Robert, S.K. (2010) Wound Healing. In: Robinson, J.K., William, H., Daniel, M.S. and Alina, F., Eds., Surgery of the Skin: Prosedural Dermatology, 2nd Edition, Mosby, Maryland Heights, 95-109.
[24]  Xiao, J.W., Gangwen, H., Philip, O., Yasmin, S. and Allen, G.L. (2006) Role of TGFβ-Mediated Inflammation in Cutaneous Wound Healing. Journal of Investigative Dermatology Symposium Proceedings, 11, 112-117.
[25]  Thomas, A.W. (2007) Common and Unique Mechanisms Regulate Fibrosis in Various Fibroproliferative Diseases. The Journal of Clinical Investigation, 117, 524-529.
[26]  Wedi, B. and Kapp, A. (2001) Pathophysiologic Role of Leukotrienes in Dermatological Diseases, Potential Thera- peutic Implications. BioDrugs, 15, 729-743.
[27]  Stephan, B., Olivera, S., Michael, S.G., Harold, B. and Marjana, T.C. (2008) Growth Factors and Cytokines in Wound Healing. Wound Repair and Regeneration, 16, 585-601.
[28]  Seifert, O. and Ulrich, M. (2009) Keloid Scarring: Bench and Bedside. Archives of Dermatological Research, 301, 259-272.
[29]  Marry, B., Robert, D. and Noelynn, O. (1992) Keloid Fibroblast Exhibit an Altered Response to TGF-β. Journal of Investigative Dermatology, 99, 650-655.


comments powered by Disqus